97 related articles for article (PubMed ID: 21482491)
1. Pharmacokinetics of oxaliplatin in gastrointestinal cancer patients with malignant ascites.
Kochi M; Fujii M; Kanamori N; Kaiga T; Okubo R; Mihara Y; Takayama T
J Chemother; 2011 Feb; 23(1):28-31. PubMed ID: 21482491
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of oxaliplatin during chronomodulated infusion in metastatic gastrointestinal cancer patients: a pilot investigation with preliminary results.
Merkel U; Wedding U; Roskos M; Höffken K; Hoffmann A
Exp Toxicol Pathol; 2003 Jun; 54(5-6):475-9. PubMed ID: 12877360
[TBL] [Abstract][Full Text] [Related]
3. Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients.
Burz C; Berindan-Neagoe IB; Balacescu O; Tanaselia C; Ursu M; Gog A; Vlase L; Chintoanu M; Balacescu L; Leucuta SE; Irimie A; Cristea V
J Gastrointestin Liver Dis; 2009 Mar; 18(1):39-43. PubMed ID: 19337632
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer.
Cho HK; Lee ES; Lee JW; Park JK; Kang JH; Lee KS; Shim CK; Chung SJ; Kim DD; Kuh HJ
J Cancer Res Clin Oncol; 2006 May; 132(5):320-6. PubMed ID: 16395593
[TBL] [Abstract][Full Text] [Related]
5. Drug monitoring during FOLFOX6 therapy in a rectal cancer patient on chronic hemodialysis.
Watayo Y; Kuramochi H; Hayashi K; Nakajima G; Kamikozuru H; Yamamoto M
Jpn J Clin Oncol; 2010 Apr; 40(4):360-4. PubMed ID: 20085906
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy.
Horimatsu T; Miyamoto S; Morita S; Mashimo Y; Ezoe Y; Muto M; Chiba T
Cancer Chemother Pharmacol; 2011 Jul; 68(1):263-6. PubMed ID: 21499694
[TBL] [Abstract][Full Text] [Related]
7. Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer.
Metzger G; Massari C; Etienne MC; Comisso M; Brienza S; Touitou Y; Milano G; Bastian G; Misset JL; Lévi F
Clin Pharmacol Ther; 1994 Aug; 56(2):190-201. PubMed ID: 8062496
[TBL] [Abstract][Full Text] [Related]
8. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of oxaliplatin and non-hematological toxicity in metastatic gastrointestinal cancer patients treated with chronomodulated oxaliplatin, 5-FU and sodium folinate in a pilot investigation.
Merkel U; Farker K; Wedding U; Roskos M; Hippius M; Höffken K; Hoffmann A
Int J Clin Pharmacol Ther; 2006 Mar; 44(3):128-34. PubMed ID: 16550735
[TBL] [Abstract][Full Text] [Related]
10. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients.
Gamelin E; Bouil AL; Boisdron-Celle M; Turcant A; Delva R; Cailleux A; Krikorian A; Brienza S; Cvitkovic E; Robert J; Larra F; Allain P
Clin Cancer Res; 1997 Jun; 3(6):891-9. PubMed ID: 9815764
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters.
Burz C; Berindan-Neagoe I; Balacescu O; Todor N; Pelau D; Floares C; Kacso G; Tanaselia C; Ursu M; Vlase L; Leucuta SE; Cristea V; Irimie A
J BUON; 2010; 15(2):263-9. PubMed ID: 20658719
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin pharmacokinetics during a four-hour infusion.
Kern W; Braess J; Böttger B; Kaufmann CC; Hiddemann W; Schleyer E
Clin Cancer Res; 1999 Apr; 5(4):761-5. PubMed ID: 10213210
[TBL] [Abstract][Full Text] [Related]
13. A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
Oh SY; Kwon HC; Lee S; Lee DM; Yoo HS; Kim SH; Jang JS; Kim MC; Jeong JS; Kim HJ
Jpn J Clin Oncol; 2007 Dec; 37(12):930-5. PubMed ID: 18211984
[TBL] [Abstract][Full Text] [Related]
14. A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
Kobrinsky B; Joseph SO; Muggia F; Liebes L; Beric A; Malankar A; Ivy P; Hochster H
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1073-8. PubMed ID: 24048674
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function.
Massari C; Brienza S; Rotarski M; Gastiaburu J; Misset JL; Cupissol D; Alafaci E; Dutertre-Catella H; Bastian G
Cancer Chemother Pharmacol; 2000; 45(2):157-64. PubMed ID: 10663631
[TBL] [Abstract][Full Text] [Related]
16. Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin.
Joel SP; Papamichael D; Richards F; Davis T; Aslanis V; Chatelut E; Locke K; Slevin ML; Seymour MT
Clin Pharmacol Ther; 2004 Jul; 76(1):45-54. PubMed ID: 15229463
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic study of oxaliplatin iv chronomodulated infusion combined with 5-fluorouracil iv continuous infusion in the treatment of advanced colorectal cancer.
Cattel L; La Grotta G; Infante L; Passera R; Arpicco S; Brusa P; Bumma C
Farmaco; 2003 Dec; 58(12):1333-8. PubMed ID: 14630248
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer.
Kho Y; Jansman FG; Prins NH; Neef C; Brouwers JR
Ther Drug Monit; 2006 Apr; 28(2):206-11. PubMed ID: 16628132
[TBL] [Abstract][Full Text] [Related]
19. Ibudilast for prevention of oxaliplatin-induced acute neurotoxicity: a pilot study assessing preliminary efficacy, tolerability and pharmacokinetic interactions in patients with metastatic gastrointestinal cancer.
Teng C; Reuter SE; Blinman PL; Dhillon HM; Galettis P; Proschogo N; McLachlan AJ; Vardy JL
Cancer Chemother Pharmacol; 2020 Oct; 86(4):547-558. PubMed ID: 32949265
[TBL] [Abstract][Full Text] [Related]
20. Clinical curative effect of oxaliplatin combined with flurouracil in the treatment of gastrointestinal tumor.
Li B; Liu Y; Wang J; Xu D; Feng W; Zhuang J
Pak J Pharm Sci; 2015 May; 28(3 Suppl):1155-8. PubMed ID: 26051738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
